Immunic Inc. Stock News

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced positive unblinded safety,…

NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in

California State Teachers Retirement System grew its holdings in shares of Immunic, Inc. (NASDAQ:IMUX) by 154.5% during the second quarter, Holdings Channel reports. The firm owned 21,443 shares of the companys stock after purchasing an additional 13,017 shares during the quarter. California State Teachers Retirement Systems holdings in Immunic were worth $263,000 at the end []

Brokerages expect that Immunic, Inc. (NASDAQ:IMUX) will announce earnings of ($0.75) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Immunics earnings, with the highest EPS estimate coming in at ($0.66) and the lowest estimate coming in at ($0.86). Immunic reported earnings of ($0.46) per share in the same quarter []

NEW YORK , Nov. 23, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ: IMUX ), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt , Ph.D., Chief Executive Officer and President, will participate in a fireside chat at the Piper Sandler & Co. 33 rd Annual Virtual Healthcare Conference, taking place November 29-December 2, 2021 . The pre-recorded presentation is available for registered attendees via the Piper Sandler conference site from Monday, November 22 to Thursday, December 2 and on the "Events and Presentations" section of Immunic''s website at: https://ir.imux.com/events-and-presentations . An archived replay will be available on the company''s website for a period of 90 days after the conference. About Immunic, Inc. Immunic, Inc. (NASDAQ: IMUX ) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.

DGAP-News: Immunic, Inc. / Key word(s): Study Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis 18

Golden Green Inc. lifted its position in shares of Immunic, Inc. (NASDAQ:IMUX) by 2.3% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 87,085 shares of the companys stock after buying an additional 1,943 shares during the quarter. Golden Green Inc. owned approximately 0.33% []

JPMorgan Chase & Co. boosted its holdings in Immunic, Inc. (NASDAQ:IMUX) by 305.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,509 shares of the companys stock after buying an additional 6,409 shares during the period. JPMorgan Chase & Co.s holdings in Immunic []

Immunic, Inc. (IMUX) CEO Daniel Vitt on Q3 2021 Results - Earnings Call Transcript

NEW YORK, Nov. 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chron

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chro

NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chr

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chr

NEW YORK and GOETTINGEN, Germany, Sept. 22, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapie

NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chro